CAR-T in R/R MM: Key Safety and Efficacy Data from the KarMMA and CARTITUDE-1 Trials

During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.

During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.

Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.